RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$165.18
+0.30%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
73.1x
EV/EBITDA
75.5x
Market Cap
$9.32B
MomentumView details →
1D Return
+0.30%
YTD Return
+1.08%
RSI (14)
48.3
ValuationView details →
P/E (Fwd)
73.1x
EV/EBITDA
75.5x
Market Cap
$9.32B
RSI (14)
48.3
MomentumView details →
1D Return
+0.30%
YTD Return
+1.08%
SummaryUpdated Jun 1, 2026
Repligen Corporation (NASDAQ:RGEN) is a leading bioprocessing technology company founded in 1981 and headquartered in Waltham, Massachusetts. The company went public in 1986 and has evolved from its origins as a biotechnology research company into a specialized provider of critical tools and technologies used in the manufacturing of biological drugs. Repligen serves the global biopharmaceutical industry by supplying essential equipment, consumables, and systems that enable the production of life-saving biologics including monoclonal antibodies, vaccines, cell and gene therapies, and other advanced therapeutic modalities.
Similar companies
Latest newsMore news →
Repligen and BioLife Solutions received US antitrust approval for their $1.5 billion merger as the Hart-Scott-Rodino waiting period expired on September 3, 2026.4d agoB. Metzler seel. Sohn & Co. AG acquired a new position of 26,361 shares in Repligen Corporation, valued at approximately $3.60 million, during the second quarter, as disclosed in its SEC filing.22d ago